病情分析:乳腺癌的IDFS和DFS是两个不同的概念。IDFS是指无疾病生存期(invasivedisease-freesurvival),而DFS是指疾病无进展生存期(disease-freesurvival)。 具体来说,IDFS包括对初始乳腺癌的治疗成功后,在接下来的时间内没有出现新的浸润性乳腺癌或其他类型的肿瘤。这个时间通常被定义为手术后5年或10年。因此,IDFS是...
此外,在肿瘤学领域,IDFS代表无浸润性肿瘤复发生存率(invasive disease-free survival),是乳腺癌治疗后无浸润性癌复发率的评估指标。这一概念的提出是为了区分原位癌,更专注于浸润性癌的复发情况,成为评估乳腺癌治疗效果的重要标准。 IDFS的工作原理 在数学领域,IDFS通过计算逆离散傅立叶级数的系数,...
乳腺癌的DFS和IDFS的区别,主要在于是否有浸润性癌的出现。两者统计差别的数字,即原位癌出现复发转移的数字。两者密切相关而又不等同,DFS是指disease疾病、Free没有疾病、survival生存,即没有疾病的生存,翻译为无病生存。IDFS中的I是指invasive,即浸润性疾病,整体而言就是无浸润性癌生存。DFS指的是既没有浸润性疾病...
乳腺癌的IDFS和DFS是两个不同的概念。IDFS是指无疾病生存期(invasivedisease-freesurvival),而DFS是指疾病无进展生存期(disease-freesurvival)。具体来说,IDFS包括对初始乳腺癌的治疗成功后,在接下来的时间内没有出现新的浸润性乳腺癌或其他类型的肿瘤。这个时间通常被定义为手术后5年或10年。因此,IDFS是指在这段...
1.Gabriel N. Hortobagyi, et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis...
Hortobagyi GN, Lacko A, Sohn J, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2024 Oct 21:S0923-7534(24)04...
5-year invasive disease-free survival showed no difference between low Ki67 (89.5%), intermediate Ki67 (79.9%), and high Ki67 (80.9%) groups (p=0.77).Conclusions:In this study, Ki67 did not predict pCR in HER2-positive breast cancer, providing no additional clinical value. HER2 IHC score ...
Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial 瑞波西利(RIB)+非甾体类芳香化酶抑制剂(NSAI)辅助治疗HR+/HER2−早期乳腺癌患者:NATALEE...
cancer recurrence or death from any cause (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p<0.0001) compared to Herceptin as an adjuvant treatment in people with HER2-positive EBC who have residual invasive disease after neoadjuvant taxane and Herceptin-based ...